Everything to know about the 10 drugs in the first Medicare price negotiations

The cost of Merck’s Januvia went down 79% to $113 from a list price of $527. The diabetes drug was used by about 843,000 Medicare enrollees in 2023 and accounted for over $4 billion in Medicare drug spending that year.

Novo Nordisk’s Fiasp and Novo Log insulins were reduced 76% to $119 from list prices of $527. The diabetes drugs were used by about 785,000 Medicare enrollees in 2023 and accounted for over $2.6 billion in Medicare drug spending that year.

AstraZeneca’s Farxiga was reduced 68% to $178.50 from a list price of $556. Farxiga was used by about 994,000 Medicare enrollees in 2023 to treat conditions like diabetes, heart failure, and kidney disease. It accounted for over $4.3 billion in Medicare drug spending that year.

The cost of Amgen’s Enbrel was lowered 67% to $2,355 from a list price of $7,106. The psoriasis and arthritis medication was used by about 48,000 Medicare enrollees in 2023. It accounted for over $2.9 billion in Medicare drug spending that year.

The cost of Boehringer Ingelheim’s Jardiance went down 66% to $197 from a list price of $573. The drug was used by over 1.88 million Medicare enrollees in 2023 to treat conditions like diabetes, heart failure, and chronic kidney disease. It accounted for over $8.8 billion in Medicare drug spending that year.

Janssen’s Stelara was reduced 66% to $4,695 from a list price of $13,836. The drug was used by 23,000 Medicare enrollees in 2023 to treat conditions like psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It accounted for over $2.9 billion in Medicare drug spending that year.

Jannsen’s Xarelto went down 62% to $197 from a list price of $517. The blood thinner was used by about 1.3 million Medicare enrollees in 2023 and accounted for over $6.3 billion in Medicare drug spending that year.

Bristol Myers Squibb’s Eliquis was reduced 56% to $231 from a list price of $521. The blood thinner was used by about 3.9 million Medicare enrollees in 2023 and accounted for a whopping $18.2 billion in Medicare drug spending that year.

Novartis’s Entresto went down 53% to $295 from a list price of $628. The drug was used by about 664,000 Medicare enrollees in 2023 to treat heart failure. It accounted for over $2.9 billion in Medicare drug spending that year.

The price of Pharmacyclics’s Imbruvica was cut 38% to $9,319 from a list price of $14,934. The blood cancer treatment was used by just 17,000 Medicare beneficiaries in 2023 and made up $2.3 million in drug spending that year.